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Abstract
An urgent requirement exists for new prognostic and predictive
assays in breast cancer. Despite the development of high-
throughput technologies such as DNA microarrays, it would now
appear that immunohistochemistry (IHC) may play an increasingly
important role in the clinical management of breast cancer. In this
editorial, the authors discuss the potential prognostic ability of a
panel of IHC markers, and question whether this well-established
assay technology may in fact allow for improved prognostic and
predictive tests in breast cancer.
Breast cancer, like many other types of cancer, is a complex
heterogeneous disease controlled by a multitude of genetic
and epigenetic alterations. It is now a well-recognised fact
that conventional prognostic and predictive markers fail to
capture this heterogeneity in the clinical setting. In this issue
of  Breast Cancer Research, Crabb and colleagues [1]
describe a novel eight-marker, immunohistochemistry (IHC)-
based, prognostic test for patients with advanced lymph-
node-positive (more than four positive lymph nodes) disease.
The eight markers included in the analysis were estrogen
receptor (ER), progesterone receptor (PR), Ki-67, Her2, epi-
dermal growth factor receptor, cytokeratin 5/6, p53 and
carbonic anhydrase IX (CA IX). The group used a selected
set of tissue microarrays (TMAs) constructed from a  well-
established, population-based cohort (n = 4,444) from British
Columbia to both test and validate their approach.
Multivariate analysis of all tumours with at least four positive
lymph nodes (n = 602) revealed that tumour size, percentage
of positive lymph nodes, PR, Ki-67 and CA IX were significant
predictors of recurrence-free survival. The group randomly
selected test and validation sets within their cohort and used
a novel score to stratify patients into three groups, based on
the expression of the eight markers. Interestingly, whereas
they had excellent results in their test set, the prognostic
strength of the eight-marker test was markedly reduced in the
validation set. The paper raises important issues.
Our understanding of the underlying molecular mechanisms
in breast cancer has increased exponentially over the last two
decades. Technologies such as DNA microarrays, mass
spectrometry-based proteomics and metabolomics have
revolutionised translational research over the last decade.
The application of DNA microarray technology, in particular,
has led to an ever-growing comprehension of the complexity
of the underlying pathophysiological pathways and inter-
actions within a breast tumour [2]. There is no doubt that gene
expression studies are an excellent platform for discovery;
however, it is debatable whether they will ever be clinically
applicable due to their prohibitive cost, reliance on frozen
tissue and the advanced technical expertise required to use
the technology. TMAs are an ideal platform for developing an
IHC-based surrogate of a gene expression profile and
enabling groups to reduce an assay to clinical utility [3].
The development of IHC was initially credited to Coons and
Jones [4], who established an immunofluorescent technique
for the detection of bacteria. It was not until the late 1970s
that IHC became a standard tool in diagnostic pathology. In
more recent times, IHC has been used to predict response to
therapy in patients with cancer (for example, the measure-
ment of ER and Her2 expression in relation to tamoxifen and
trastuzumab treatment, respectively). With the advent of
TMAs and high-throughput pathology, new demands have
been placed on the quality, reproducibility and accuracy of
IHC assays, many of which have been addressed and led to
the development of IHC surrogates.
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It is quite plausible that IHC surrogates may be a more appro-
priate clinical assay than gene expression-based platforms in
the future. As demonstrated by Nielsen and colleagues [5]
and Carey and colleagues [6], it is possible to identify
molecular subgroups (Luminal A, Luminal B, Basal and Her2)
using a small number of IHC markers. Likewise, Ring and
colleagues [7] have reported on a novel panel of five anti-
bodies which can predict outcome in ER-positive tumours.
Additionally, it has recently been demonstrated that a number
of the different prognostic gene expression signatures
developed over the last 5 years showed significant agree-
ment in outcome prediction in a single cohort of patients [8].
As there was a minimal overlap of genes used in each of the
prognostic signatures, these findings would suggest that they
are all tracking a similar phenotype, which may be possible to
identify using a panel of IHC markers in the future.
Traditionally, the main obstacle to IHC has been the lack of
high-quality specific antibodies. However, the development of
high-throughput antibody-based proteomic resources
promises to help overcome this obstacle. Recently, a compre-
hensive atlas of human protein expression patterns has been
generated through the Human Protein Atlas (HPA) program
[9,10]. At present, more than 3,000 antibodies (corres-
ponding to more than 2,600 different human proteins) have
been screened on TMAs comprised of 48 types of normal
tissues, 216 human tumours representing the 20 most
common forms of human cancer and 47 cell lines [11,12]. It
is believed that resources such as the HPA will herald a new
era for IHC-based diagnostic, prognostic and predictive tests.
Another issue raised by Crabb and colleagues is that of
biomarker validation. One of the disappointing aspects of the
post-genomic era is that while a plethora of putative
biomarkers have undergone preliminary clinical evaluations,
only a small minority have received regulatory approval for
clinical use. This apparent bottleneck in transfer from
biomarker discovery to clinical application is primarily due to a
lack of rigorous validation of emerging biomarkers. In 2004, a
standard template, called the Standards for Reporting of
Diagnostic Accuracy (STARD) initiative, was developed to
encourage the use of standards for the reporting of
diagnostic accuracy for new tests [13]. Unfortunately, many
of the studies published regarding new candidate biomarkers
fail to meet these standards. In particular, the studies are
often performed on small retrospective cohorts and lack
power; additionally, many biomarker studies fail to include an
independent validation stage, whereby the biomarker is
evaluated using a second independent cohort of patients.
This, however, can be a time-consuming process and the
approach taken by Crabb and colleagues, in which they split
their cohort into test and validation sets and saw a marked
difference in the prognostic strength of their IHC panel
between the test and validation sets, is worth noting. Despite
these findings, it would be beneficial to examine the eight-
marker prognostic test in an independent cohort, particularly
given the fact that only half of the patients in the study by
Crabb and colleagues received adjuvant chemotherapy.
Current clinical guidelines would advocate adjuvant chemo-
therapy for all patients with advanced nodal disease [14].
Interestingly, Crabb and colleagues demonstrated that 76%
of patients who scored highest on their prognostic test, and
thus had a significantly worse prognosis, had received
chemotherapy. This would suggest that the eight-marker test
warrants investigation in a cohort in which all patients
received chemotherapy and may provide interesting data
regarding resistance to adjuvant chemotherapy.
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